Table 1

Summary of data used for comparative evaluation of 8 predicted T-cell epitopes of Pep1, Amn1, and Plb antigensa

Synthetic epitope peptideSequence of computationally predicted epitope peptidesProPred binding prediction (% of alleles)ELISPOT assay (no. of spots per well)DELFIA (IC50 [nM])b% sequence similarity between speciescHomology to human proteins (E-value)dNo. of nonsynonymous coding SNPe
  • a The synthetic epitope peptides listed are those predicted to bind to >80% of 51 human MHC II alleles in the ProPred algorithm. The same peptides were also shown to stimulate IFN-γ production by immune CD4+ T cells (measured by ELISPOT assays) as previously reported (46, 47). The synthetic peptides indicated in bold type were ultimately selected for incorporation into an epitope-based vaccine construct.

  • b Peptide concentrations that showed 50% inhibition of CLIP binding to HLA-DR4 transgenic mouse-derived major histocompatibility class II (MHC II) molecules in the DELFIA.

  • c Results of alignment of peptide sequences of C. immitis and C. posadasii isolates using the Broad Institute Coccidioides Group database.

  • d E-values of the results of an NCBI BLASTP search of peptide sequence similarities (1) with proteins in the Homo sapiens protein database.

  • e Numbers of nonsynonymous coding single-nucleotide polymorphisms (SNP) identified for each peptide sequence (37).